Full Text of HR0585 102nd General Assembly
HR0585 102ND GENERAL ASSEMBLY |
| | HR0585 | | LRB102 22556 MST 31697 r |
|
| 1 | | HOUSE RESOLUTION
| 2 | | WHEREAS, Breast cancer is among the most commonly | 3 | | diagnosed types of cancer and is the second leading cause of | 4 | | cancer death among women in the United States; and
| 5 | | WHEREAS, Approximately 281,550 women will be diagnosed | 6 | | with breast cancer, and nearly 43,600 will die with this | 7 | | malignancy in 2021; and
| 8 | | WHEREAS, Triple Negative Breast Cancer is one of many | 9 | | forms of breast cancer and accounts for approximately 15-30% | 10 | | of all diagnosed invasive breast cancer cases in the United | 11 | | States; and | 12 | | WHEREAS, Of the new breast cancer cases diagnosed in 2019 | 13 | | in the United States, more than 53,700 were Triple Negative | 14 | | Breast Cancer with higher prevalence among younger women, | 15 | | Black and Hispanic women, women with type 2 diabetes or | 16 | | carrying excess weight in the abdomen area, and those with | 17 | | BRCA1 mutations; and | 18 | | WHEREAS, Due to its aggressive behavior, Triple Negative | 19 | | Breast Cancer grows quickly and is more likely to have spread | 20 | | at the time it is found and more likely to return after | 21 | | treatment than other types of breast cancer; and |
| | | HR0585 | - 2 - | LRB102 22556 MST 31697 r |
|
| 1 | | WHEREAS, People diagnosed with metastatic Triple Negative | 2 | | Breast Cancer have a less than 30% chance of surviving past | 3 | | five years; and | 4 | | WHEREAS, Triple Negative Breast Cancer cells do not | 5 | | contain and are considered negative for the three key | 6 | | receptors that medicines typically target in other types of | 7 | | breast cancers; therefore, there are limited treatment options | 8 | | that can be used to treat this type of cancer; and | 9 | | WHEREAS, Patients with an early diagnosis can often be | 10 | | treated with chemotherapy, radiation, and surgery; however, | 11 | | the limited therapies available that specifically address the | 12 | | management of Triple Negative Breast Cancer have made treating | 13 | | this disease a challenge for clinicians; and | 14 | | WHEREAS, Recent innovations in targeted therapies have | 15 | | fueled advances in the fight against Triple Negative Breast | 16 | | Cancer; and
| 17 | | WHEREAS, Studies have shown that Triple Negative Breast | 18 | | Cancer disease-specific mortality rates are often higher if | 19 | | patients have Medicaid or Medicare or are lower socio-economic | 20 | | status, and compared with non-Hispanic white women, Black | 21 | | women are 48% less likely to receive guideline adherent care |
| | | HR0585 | - 3 - | LRB102 22556 MST 31697 r |
|
| 1 | | and have an approximate two-fold higher mortality incidence, | 2 | | resulting in a disproportionately higher risk of death from | 3 | | Triple Negative Breast Cancer; and
| 4 | | WHEREAS, Advances in breast cancer screening and treatment | 5 | | over the last few decades have reduced the overall breast | 6 | | cancer mortality rate, yet the disproportionate impact of | 7 | | Triple Negative Breast Cancer on racial and ethnic minority | 8 | | communities raises the need for consideration of the | 9 | | underlying determinants driving the disparities; and
| 10 | | WHEREAS, It is necessary to promote Triple Negative Breast | 11 | | Cancer education, to raise awareness about the disease-related | 12 | | disparities, and to tackle inequities within the health care | 13 | | delivery, such as inadequate access to screening, diagnostic | 14 | | testing, and care, to improve early detection and survival; | 15 | | therefore, be it
| 16 | | RESOLVED, BY THE HOUSE OF REPRESENTATIVES OF THE ONE | 17 | | HUNDRED SECOND GENERAL ASSEMBLY OF THE STATE OF ILLINOIS, that | 18 | | we declare March 3, 2022 as Triple Negative Breast Cancer | 19 | | Awareness Day in the State of Illinois and the month of March | 20 | | 2022 as Triple Negative Breast Cancer Awareness Month; and be | 21 | | it further | 22 | | RESOLVED, That we support legislation to reduce Triple |
| | | HR0585 | - 4 - | LRB102 22556 MST 31697 r |
|
| 1 | | Negative Breast Cancer disparities in early detection and | 2 | | survival by improving education and awareness through health | 3 | | promotion initiatives targeting underserved communities | 4 | | disproportionately impacted, by ensuring equitable access to | 5 | | and the affordability of breast cancer screening, genetic | 6 | | counseling, and diagnostic testing, by promoting cultural | 7 | | sensitivity and workforce diversity policies in health care | 8 | | provider training, and by guaranteeing timely patient access | 9 | | to clinically appropriate treatment options identified in the | 10 | | National Comprehensive Cancer Network (NCCN) guidelines; and | 11 | | be it further | 12 | | RESOLVED, That additional legislative provisions should be | 13 | | examined to safeguard affordable, continuous, and equitable | 14 | | patient access to Triple Negative Breast Cancer related care, | 15 | | services, and medicines along the entire continuum of care.
|
|